Insilico Announces Preclinical Candidate for Inhalable Formulation of Generative AI IPF Drug
VloĆŸit
- Äas pĆidĂĄn 26. 07. 2023
- đŁ Announcing the preclinical candidate for an inhalation solution of ISM001-055, the first anti-fibrotic small molecule inhibitor developed leveraging Insilico's proprietary AI drug discovery platform Pharma.AI for the treatment of the chronic progressive lung disease Idiopathic Pulmonary Fibrosis (IPF).
â With promising preclinical results, Insilico is proceeding with IND filing as the first AI drug discovery company to venture into nebulized formulations.
â Potential advantages for the inhalation solution include a smaller effective dose, larger safety window, and reduced side effects.
â As demonstrated in preclinical studies, the inhalation solution of ISM001-055 is well tolerated with good anti-fibrotic and anti-inflammatory efficacy, favorable safety and pharmacokinetic (PK) profiles, and no local or systemic toxicity observed.
Learn more: www.eurekalert.org/news-relea... - VÄda a technologie
When will the new dug be available?
God Gave Noah the Rainbow Sign
No More Water but Fire Next Time
đđđ„đĄđđ¶đ„đ€”đ°â€ïžâđ„đ€Žđž